Andrew Fenny Joins Pace Life Sciences as President

Pace, a Science and Technology company, has appointed Andrew Fenny as President of Pace Life Sciences, to lead the life sciences division into its next phase of strategic growth with a focus on expanding support and capacity for pharmaceutical and biotech clients across the development cycle.

Based out of Research Triangle Park in North Carolina, Fenny will lead all aspects of the division, build collaboration across all 8 Pace Life Sciences sites, and direct the delivery of the organization’s service capabilities to support customers from early development through clinical supply and commercialization.

“Andy joins Pace at a time when our customers need more than results. They need a partner who can help them navigate complex regulatory pathways and challenging market conditions,” said Ken Beyer, CEO at Pace. “Andy’s leadership and expertise will help us deliver the certainty companies need at every stage of the product lifecycle because every phase drives programs closer to patients waiting on treatments that change lives.”

Experience

Fenny brings over two decades of experience across the CDMO and pharmaceutical sectors. He joins Pace Life Sciences from SK Pharmteco where he served as Chief Commercial Officer. Prior to that role, he worked for FUJIFILM Diosynth Biotechnologies as Chief Business Officer. His experience spans commercial strategy, business development, integrated operations, and client experience.

“Pace Life Sciences has a strong foundation of scientific expertise, technical talent, and customer commitment,” said Fenny. “As life sciences organizations look for partners who can help deliver with speed and accuracy amidst evolving challenges, Pace is well positioned to deliver integrated support so these organizations can move forward with greater confidence and continuity.”